[go: up one dir, main page]

MX2010008720A - Composiciones, metodos y estuches para mejorar la respuesta inmunitaria a una enfermedad respiratoria. - Google Patents

Composiciones, metodos y estuches para mejorar la respuesta inmunitaria a una enfermedad respiratoria.

Info

Publication number
MX2010008720A
MX2010008720A MX2010008720A MX2010008720A MX2010008720A MX 2010008720 A MX2010008720 A MX 2010008720A MX 2010008720 A MX2010008720 A MX 2010008720A MX 2010008720 A MX2010008720 A MX 2010008720A MX 2010008720 A MX2010008720 A MX 2010008720A
Authority
MX
Mexico
Prior art keywords
immune response
enhancing immune
respiratory condition
kits
compositions
Prior art date
Application number
MX2010008720A
Other languages
English (en)
Inventor
James Patrick Ebel
Jeffrey Warren Clymer
Lucy Anne Gildea
David Alexander Lawson
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MX2010008720A publication Critical patent/MX2010008720A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describen composiciones para tratar una afección respiratoria, preferentemente, mediante la mejora de una respuesta inmunitaria en un mamífero. Las composiciones incluyen una cantidad terapéutica de una cepa de bacterias probióticas y una cantidad terapéutica de un componente adicional. También se incluyen métodos de tratamiento de una afección respiratoria, preferentemente, mediante la mejora de la respuesta inmunitaria en un mamífero. Los estuches contienen las composiciones, y también se incluyen las instrucciones para aplicar los métodos. El método incluye la administración oral al mamífero de una cantidad terapéutica de una cepa de bacterias probióticas y una cantidad terapéutica de un componente adicional.
MX2010008720A 2008-02-06 2009-02-06 Composiciones, metodos y estuches para mejorar la respuesta inmunitaria a una enfermedad respiratoria. MX2010008720A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6373508P 2008-02-06 2008-02-06
PCT/US2009/033391 WO2009100331A2 (en) 2008-02-06 2009-02-06 Compositions methods and kits for enhancing immune response to a respiratory condition

Publications (1)

Publication Number Publication Date
MX2010008720A true MX2010008720A (es) 2010-08-30

Family

ID=40791057

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008720A MX2010008720A (es) 2008-02-06 2009-02-06 Composiciones, metodos y estuches para mejorar la respuesta inmunitaria a una enfermedad respiratoria.

Country Status (10)

Country Link
US (2) US20090196921A1 (es)
EP (1) EP2268793A2 (es)
JP (1) JP2011510684A (es)
CN (1) CN101939411A (es)
AU (1) AU2009212295A1 (es)
BR (1) BRPI0908348A2 (es)
CA (1) CA2713525A1 (es)
MX (1) MX2010008720A (es)
RU (1) RU2010132283A (es)
WO (1) WO2009100331A2 (es)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006520804A (ja) * 2003-03-21 2006-09-14 ケー２エイ インコーポレイテッド ジュカラ及びアサイ果実ベースの健康補助食品
BG110506A (bg) * 2009-10-27 2011-05-31 "Селур Вк Холдинг" Еоод Нови щамове млечно-кисели бактерии и техни комбинации за получаване на пробиотични препарати
WO2011059474A1 (en) * 2009-10-30 2011-05-19 Nestec S.A. Methods for maintaining eye health and ameliorating opthalmic maladies in canines
TW201121431A (en) * 2009-12-01 2011-07-01 Abbott Lab Soy protein-based nutritional formula with superior stability
AU2011261528A1 (en) * 2010-06-01 2013-01-10 Moore Research Enterprises Llc Cellular constituents from Bacteroides, compositions thereof, and therapeutic methods employing Bacteroides or cellular constituents thereof
HK1253538A1 (en) * 2010-08-04 2019-06-21 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them
US20120135127A1 (en) * 2010-11-29 2012-05-31 Sheng Chun Tang Pharmaceutical Industrial Co., Ltd. Dispersion having particles of ganoderma lucidum
JP5840368B2 (ja) * 2011-02-02 2016-01-06 カルピス株式会社 関節炎予防改善用物質
WO2012140636A1 (en) * 2011-04-11 2012-10-18 Alimentary Health Limited A probiotic formulation
GB201110095D0 (en) * 2011-06-15 2011-07-27 Danisco Method of treatment
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
DE102012101864A1 (de) * 2012-03-06 2013-09-12 Gramme-Revit Gmbh Mittel zur Behandlung von Allergien und anderen Erkrankungen
TWI481409B (zh) * 2013-01-10 2015-04-21 Conmed Pharmaceutical & Bio Medical Corp 一種使用益生菌製備用於清除尿毒素之組合物的用途
US20160030493A1 (en) * 2013-03-14 2016-02-04 Gil NOFAR Inhibition of Neurodegenerative Disease by Grape Seed Extract, Green Tea Extract and Probiotic Bacteria
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
EA029476B1 (ru) * 2013-04-19 2018-03-30 Актиженомик Са Микропищевые добавки для иммунитета
WO2014195479A1 (en) * 2013-06-07 2014-12-11 Nerthus Aps Dry preparation of alpinia galanga or alpinia conchigera with high content of 1's-1'-acetoxychavicol acetate
EP3068404B1 (en) * 2013-11-15 2021-01-06 Société des Produits Nestlé S.A. Compositions for use in the prevention or treatment of urt infections in infants or young children at risk
CN103734732B (zh) * 2014-01-27 2015-08-05 杨子驿 呼吸道保健的清咽利气食品
TWI505832B (zh) 2014-02-21 2015-11-01 Genmont Biotech Inc 乳酸菌、其組合物與彼等於治療自體免疫疾病暨其倂發症之用途
SG11201701577WA (en) * 2014-08-29 2017-04-27 Wakamoto Pharma Co Ltd Lactic acid bacteria-containing composition
EP3015110A1 (en) * 2014-10-28 2016-05-04 D.M.G. Italia Srl Biological barrier with cystein for the use in the treatment of naso-pharyngo-tubal infections
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
LT3065748T (lt) 2014-12-23 2018-03-12 4D Pharma Research Limited Bacteroides thetaiotaomicron padermė ir jos panaudojimas uždegimo sumažinimui
SMT202200174T1 (it) 2015-06-15 2022-05-12 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
SG10201912323VA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3307288T3 (pl) 2015-06-15 2019-12-31 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
RU2018105356A (ru) 2015-08-27 2019-09-30 Дзе Проктер Энд Гэмбл Компани Бифидобактерия bifidobacterium longum
US20180280453A1 (en) * 2015-08-27 2018-10-04 Alimentary Health Limited Use of bifidobacterium longum and an exopolysaccharide produced thereby
WO2017062472A1 (en) * 2015-10-05 2017-04-13 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung injury
EP3359173A1 (en) * 2015-10-07 2018-08-15 Bifodan A/S Probiotic formulation
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3520801A1 (en) 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN110392734A (zh) 2017-02-28 2019-10-29 营养健康有限公司 可以有益地调节针对呼吸道病毒感染的免疫应答的长双歧杆菌
WO2018158306A1 (en) * 2017-02-28 2018-09-07 Alimentary Health Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
CN106978464B (zh) * 2017-04-28 2021-04-23 华南农业大学 一种提高蛹虫草Cm04类胡萝卜素产量的固体发酵方法
CN107080755A (zh) * 2017-04-28 2017-08-22 青岛东海药业有限公司 凝结芽孢杆菌在制备预防或治疗慢性阻塞性肺疾病制剂中的应用
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
GB201708932D0 (en) 2017-06-05 2017-07-19 Probi Ab Microbial compositions
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
MA49373B1 (fr) 2017-06-14 2021-02-26 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA49425A (fr) 2017-06-14 2020-04-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
US20180360811A1 (en) * 2017-06-16 2018-12-20 SEN-JAM Pharmaceutical LLC Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
JP2020524711A (ja) * 2017-06-21 2020-08-20 ガネーデン バイオテック インコーポレイテッド 不活性化されたバチルス・コアグランスおよび身体能力の向上のためのその使用法
US9943503B1 (en) * 2017-10-19 2018-04-17 Edward Wick Pharmaceutical composition for treating bacterial and viral infections
US12128076B2 (en) * 2018-01-12 2024-10-29 Gi Innovation, Inc. Composition comprising probiotics and polypeptide having binding affinity for IgE and use thereof
IT201800003804A1 (it) * 2018-03-21 2019-09-21 Neilos S R L Composizione per il trattamento delle patologie respiratorie e orofaringee
NL2021737B1 (en) * 2018-10-01 2020-05-07 Nutricia Nv Dietary fiber for treating patients suffering from methylmalonic acidemia and propionic acidemia
TWI713972B (zh) * 2019-01-14 2020-12-21 大江生醫股份有限公司 改善呼吸道健康之益生菌株及其組合物與用途
CN110643542B (zh) * 2019-10-25 2021-01-29 江南大学 一株可缓解变应性哮喘Th2反应的罗伊氏乳杆菌及其应用
CN110643541B (zh) * 2019-10-25 2021-08-24 江南大学 一株可调节过敏性哮喘Th2/Th1平衡的干酪乳杆菌及其应用
IT202000005011A1 (it) * 2020-03-09 2021-09-09 Sofar Spa Lattoferrina per uso orale ad azione antivirale
CN115666606A (zh) * 2020-03-09 2023-01-31 索法尔公司 用于治疗呼吸系统病毒感染的口服用细菌菌株及其组合物
EP4117697A1 (en) * 2020-03-13 2023-01-18 PrecisionBiotics Group Limited Bifidobacterium longum
IT202000006448A1 (it) 2020-03-26 2021-09-26 Sofar Spa Ceppi di batteri, loro composizioni e loro uso in un metodo per il trattamento di una carenza di vitamina d,e di disturbi associati
US20230158089A1 (en) * 2020-04-09 2023-05-25 Chandler Biopharmaceutical Corporation Probiotic compositions and methods of use
CN116726055A (zh) * 2020-04-28 2023-09-12 香港中文大学 用于提高免疫力的组合物
CN112056399A (zh) * 2020-06-28 2020-12-11 武汉康复得生物科技股份有限公司 一种增强免疫力的益生菌组合物及其应用
US11318174B2 (en) * 2020-07-09 2022-05-03 Dupont Nutrition Biosciences Aps Probiotics for use in the prevention or treatment of illness and/or symptoms associated with coronaviruses
CN111743922B (zh) * 2020-07-14 2022-03-29 华熙生物科技股份有限公司 一种提高益生菌在鼻腔中的定植和活性的组合物及在鼻腔护理中的应用
US20220040228A1 (en) * 2020-08-10 2022-02-10 Frank Gaertner Materials and methods for stopping respiratory virus infections
KR20230098618A (ko) * 2020-11-12 2023-07-04 신바이오틱스 아베 신바이오틱 조성물
US20220265738A1 (en) * 2021-02-12 2022-08-25 University Of South Florida Salutary effects of indigenous probiotics and nanoaerosol methods to mitigate microbial infections including covid 19
US12186358B2 (en) 2021-02-17 2025-01-07 Plexus Worldwide, Llc Compositions and methods for supporting immune health
US20240139264A1 (en) * 2021-02-23 2024-05-02 Societe Des Produits Nestle S.A. Composition and kit for alleviating symptoms of respiratory allergy in toddlers
US20230113990A1 (en) * 2021-06-29 2023-04-13 Daniel E. Bucci Nutritional drink
TW202323517A (zh) * 2021-10-28 2023-06-16 香港中文大學 用於增強ｃｏｖｉｄ疫苗接種效力和減少來自ｃｏｖｉｄ疫苗接種的不良影響的組合物和方法
EP4452282A4 (en) * 2021-12-22 2025-10-29 Terence Francis Mullins SYSTEM AND METHOD FOR ANTIBODY ACTIVATORS IN AN AQUEOUS IODINE SOLUTION
WO2023137382A1 (en) * 2022-01-12 2023-07-20 Trope Hillel Dog biscuit
CN115737690B (zh) * 2022-11-11 2024-04-19 重庆医科大学 约氏乳杆菌在制备用于缓解急性呼吸窘迫综合征的药物中的应用
CN116726054B (zh) * 2022-12-05 2024-03-26 山东新时代药业有限公司 一种即食型益生菌组合物及其制备方法、用途
JP2025172664A (ja) * 2024-05-13 2025-11-26 我的輕食有限公司 微粒子状物質による肺損傷の改善用組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002607A1 (en) * 1994-07-14 1996-02-01 E.I. Du Pont De Nemours And Company Refrigerant compositions
US7432097B2 (en) * 1997-08-13 2008-10-07 Verenium Corporation Phytases, nucleic acids encoding them and methods of making and using them
US20040161422A1 (en) * 1999-04-30 2004-08-19 Natarajan Ranganathan Nutritional compositions comprising probiotics
TWI300714B (en) * 2001-04-27 2008-09-11 Ajinomoto Kk Immunopotentiators
US6764819B2 (en) * 2002-07-16 2004-07-20 Emp Biotech Gmbh Method for chemiluminescent detection
AU2004227998A1 (en) * 2003-04-02 2004-10-21 Pharmachem Laboratories, Inc. Novel probiotic compositions and methods of using the same
US20050100559A1 (en) * 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
WO2006048457A1 (en) * 2004-11-05 2006-05-11 Dsm Ip Assets B.V. Probiotica and polyphenol

Also Published As

Publication number Publication date
AU2009212295A1 (en) 2009-08-13
WO2009100331A2 (en) 2009-08-13
WO2009100331A3 (en) 2009-12-17
US20090196921A1 (en) 2009-08-06
JP2011510684A (ja) 2011-04-07
BRPI0908348A2 (pt) 2015-07-28
CN101939411A (zh) 2011-01-05
RU2010132283A (ru) 2012-03-20
EP2268793A2 (en) 2011-01-05
CA2713525A1 (en) 2009-08-13
US20120114608A1 (en) 2012-05-10

Similar Documents

Publication Publication Date Title
MX2010008720A (es) Composiciones, metodos y estuches para mejorar la respuesta inmunitaria a una enfermedad respiratoria.
MX2010005642A (es) Preparados, metodos y estuches para el tratamiento de la tos.
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
IN2015DN02826A (es)
WO2012092364A3 (en) Method for sympathetic rebalancing of patient
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
MY195289A (en) Anti IL-36R Antibodies
GB0920703D0 (en) Compositions containing satiogens and methods of use
MY194587A (en) Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration
PH12014500075A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MY159630A (en) Pharmaceutical composition comprising linagliptin and optionally a sglt2 inhibitor, and uses thereof
MY157473A (en) Antibody molecules having specificity for human ox40
GB2503852A (en) Compounds for the treatment of neuropsychiatric disorders
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
WO2009080800A3 (en) Method for decreasing abdominal girth by administering a bifidobacterium bacteria
WO2014043696A3 (en) Compositions and methods for treating amyotrophic lateral sclerosis
MX2018008882A (es) Composicion y metodo para el diagnostico y tratamiento de trastornos relacionados con hierro.
WO2009008656A3 (en) A soap composition for atopic dermatitis containing fermented extract of xanthium strumarium l. and preparation method thereof
MD20160066A2 (ro) Modulatoare alosterice pozitive ale receptorului nicotinic acetilcolinic
MX2015005111A (es) Composicion a base de hierbas para la prevencion y tratamieto de tnf-a una enfermedad mediada.
MX356814B (es) Métodos y composiciones para neuroprotección.
AU2017221784B2 (en) Novel compositions and methods for the treatment of immune related diseases
UA35047U (ru) Способ проведения оздоровительной гимнастики
UA56675U (ru) Способ местного лечения генерализованного пародонтита c использованием синглетно-кислородной терапии
UA27828U (en) Method for treating prosthetic stomatitis against the background metabolic syndrome

Legal Events

Date Code Title Description
FA Abandonment or withdrawal